Form 4: Akoya Biosciences Executive Niro Ramachandran Reports Stock Transactions
SEC Form 4 Filing
Niro Ramachandran, Chief Business Officer of Akoya Biosciences, reports the withholding of shares to cover taxes on restricted stock unit awards.
Summary
- Niro Ramachandran, Chief Business Officer of Akoya Biosciences, filed a Form 4 detailing changes in beneficial ownership.
- The report indicates that shares were withheld to cover taxes on restricted stock unit awards.
- Specifically, 2,310 shares were withheld on March 1, 2025, at a price of $1.63 per share, related to an award granted on February 23, 2023.
- Additionally, 3,594 shares were withheld on March 1, 2025, at a price of $1.63 per share, related to an award granted on February 22, 2024.
- Following these transactions, Ramachandran directly owns 289,520 shares of Akoya Biosciences common stock.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates the vesting of stock awards and the subsequent withholding of shares to cover tax obligations, a common practice in executive compensation.
Key Dates
| Date | Description |
|---|---|
| February 23, 2023 | Date of restricted stock unit award that vests in four annual installments beginning March 1, 2024. |
| February 22, 2024 | Date of restricted stock unit award that vests in four annual installments beginning March 1, 2025. |
| March 1, 2024 | First vesting date of the restricted stock unit award granted on February 23, 2023. |
| March 1, 2025 | Date of stock transaction (shares withheld for taxes) and first vesting date of the restricted stock unit award granted on February 22, 2024. |
| March 4, 2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.